Australian & New Zealand Childrens Haematology/Oncology Group

Clinical Trials

BIOMEDE: Biological Medicine for Diffuse Intrinsic Pontine Glioma Eradication

Brain Tumor - Diffuse Intrinsic Pontine Glioma (DIPG)

Status: Closed to Recruitment | NSW , QLD , VIC , WA , SA , New Zealand

There is no effective treatment or cure for children diagnosed with Diffuse Intrinsic Pontine Glioma (DIPG). Current treatment for DIPG is radiation, which is, ultimately, ineffective. This trial will explore if existing chemotherapy drugs can be a safe and effective treatment. Initially the child will undergo a biopsy, performed by a specially trained neurosurgeon, to examine the unique biological characteristics of the child’s DIPG. This will determine which of the three chemotherapy drugs is given to the child during and after radiation. The data from the tissue samples and drug treatment studies will also help other children in the future.

Disease Stage: New Diagnosis

Patient Age Range:  >6 months and <25 years

Sample Size: 250

Trial Sponsors:

  • International: Institut Gustave-Roussy, France
  • National: ANZCHOG

Link to clinical trial registry

ANZCHOG acknowledges the valuable support of BIOMEDE by the Isabella and Marcus Foundation and Cure Brain Cancer Foundation.